Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies
- 16 October 2014
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (6) , 1271-1278
Abstract
Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma concentrations of each drug.Keywords
This publication has 32 references indexed in Scilit:
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2012
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI: Journal of the National Cancer Institute, 2012
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer OutcomesClinical Pharmacology & Therapeutics, 2011
- Orally administered Endoxifen is a new therapeutic agent for breast cancerBreast Cancer Research and Treatment, 2010
- Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparisonXenobiotica, 2004
- Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast CancerClinical Pharmacokinetics, 1992
- Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenograftsEuropean Journal of Cancer and Clinical Oncology, 1989
- Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significanceBreast Cancer Research and Treatment, 1982
- Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifenThe Journal of Steroid Biochemistry and Molecular Biology, 1982
- Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model1980